Magnesium silicate
ALIMENTARY TRACT AND METABOLISM
Also known as: magnesium mesotrisilicate, magnesium trisilicate, trisilicalm
Data last refreshed: (DrugCentral release 2024-11-01)
Key facts
Magnesium silicate is a drug catalogued in DrugCentral. It was first approved by the FDA in 1983. Recorded indications include Gastric Hypersecretory Conditions, Gastroesophageal reflux disease, Heartburn and Hiatal Hernia with Reflux Esophagitis.
- Indications: Gastric Hypersecretory Conditions, Gastroesophageal reflux disease, Heartburn, Hiatal Hernia with Reflux Esophagitis and Indigestion and others.
- ATC code: A02AA05 (Magnesium compounds).
- Molecular formula: Mg2O8Si3; molecular weight 260.86 g/mol.
Indications & contraindications
Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).
Indications (6)
- Gastric Hypersecretory Conditions
- Gastroesophageal reflux disease
- Heartburn
- Hiatal Hernia with Reflux Esophagitis
- Indigestion
- Peptic ulcer
Off-label uses (3)
- Multiple endocrine adenomas
- Stress-Related GI Mucosal Bleeding Prevention
- Systemic mast cell disease
Contraindications (13)
- Acute nephropathy
- Aluminum intoxication
- Chronic diarrhea
- Chronic heart failure
- Constipation
- Diarrhea
- Edema
- Fecal impaction
- Gastrointestinal obstruction
- Hemorrhoids
- Hypophosphatemia
- Kidney disease
- Oliguria
Regulatory approvals (1)
| Date | Agency | Marketed as | Applicant | Orphan |
|---|---|---|---|---|
| 1983-12-09 | FDA | — | SANOFI AVENTIS US |
ATC classification
| ATC code | Therapeutic hierarchy |
|---|---|
A02AA05 | ALIMENTARY TRACT AND METABOLISM › DRUGS FOR ACID RELATED DISORDERS › ANTACIDS › Magnesium compounds |
Reported adverse-event signals
Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.
| MedDRA term | LLR |
|---|---|
| Appendicolith | 172.7 |
| Appendicitis | 143.0 |
| Blood phosphorus increased | 137.1 |
| Ventricular fibrillation | 124.3 |
| Myasthenia gravis | 108.0 |
| Cardiogenic shock | 104.2 |
| Blood uric acid increased | 91.3 |
| Ascites | 86.3 |
| Stress | 85.3 |
| Hyperphosphataemia | 84.1 |
| Carbuncle | 82.6 |
| Diabetes mellitus | 77.7 |
Chemical structure
| Molecular formula | Mg2O8Si3 |
|---|---|
| Molecular weight | 260.86 g/mol |
| CAS number | 14987-04-3 |
| InChIKey | — |
| PubChem CID | 72941442 |
Frequently asked questions
Answers are generated from the structured data on this page, not written by hand.
What is Magnesium silicate used for?
DrugCentral lists the following indications for Magnesium silicate: Gastric Hypersecretory Conditions, Gastroesophageal reflux disease, Heartburn, Hiatal Hernia with Reflux Esophagitis, Indigestion and Peptic ulcer.
When was Magnesium silicate first approved?
Magnesium silicate was first approved by the FDA in 1983.
What is the chemical formula of Magnesium silicate?
Magnesium silicate has the molecular formula Mg2O8Si3 and a molecular weight of 260.86 g/mol.
Browse: all drugs starting with M · drug guides by category · protein targets A–Z.
Sources
- DrugCentral drug card 4513 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
- ChEMBL CHEMBL2096633 — compound record and bioactivity
- PubChem CID 72941442 — chemical identifiers
- DrugBank DB09281 — drug record
- FDA UNII 9B9691B2N9 — substance identity
- DailyMed: FDA labels for Magnesium silicate — current prescribing information (label search)
- FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.